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Abstract
Background and Objective Highly purified human meno-
trophin and urofollitrophin preparations obtained from
human urine via a novel patented purification method have
been tested over a timeframe of 14 years in the studies
presented in this article. The objective of the studies was to
investigate the pharmacokinetics and the pharmacody-
namics of follicle-stimulating hormone (FSH) after single
subcutaneous and intramuscular doses and multiple sub-
cutaneous doses of the tested preparations in healthy fertile
pituitary-suppressed women.
Designs We performed five open, randomised, crossover,
single-dose bioequivalence and/or bioavailability studies
and one open, multiple-dose, pharmacokinetics and phar-
macodynamics study.
Study Subjects and Treatments The six studies included
121 healthy fertile women taking their usual combined oral
contraceptives for 3 months before the study: Study 1: 300
international units (IU) of highly purified menotrophin as
single subcutaneous and intramuscular doses. Study 2: 300
IU of highly purified menotrophin (test formulation vs.
comparator) as single subcutaneous doses. Study 3: 300 IU
of highly purified urofollitrophin (hp-FSH) (test formula-
tion vs. comparator) as single subcutaneous doses. Study 4:
300 IU (2 9 150 IU vs. 4 9 75 IU) of hp-FSH as single
subcutaneous doses. Study 5: 225 and 445 IU of hp-FSH as
single subcutaneous doses. Study 6: daily 225 IU of hp-
FSH as subcutaneous doses for 5 consecutive days.
Main Outcome Measures The main outcome measures
were the FSH pharmacokinetic parameters, estradiol con-
centrations, and the number and size of the follicles.
Results FSH after single subcutaneous and intramuscular
injections of menotrophin or urofollitrophin attained a sys-
temic peak (maximum) concentration (Cmax) that was on
average consistent throughout the first four studies and
ranged from 4.98 to 7.50 IU/L. The area under the plasma
concentration–time curve (AUC) from administration to the
last observed concentration time t (AUCt) ranged from
409.71 to 486.16 IU/Lh and the elimination half-life (t)
ranged from 39.02 to 53.63 h. After multiple doses of uro-
follitrophin (225 IU) for 5 days, FSH attained a mean Cmax
of 14.93 ± 2.92 IU/L and had an AUC during the time
interval s between two consecutive doses at steady state
(AUCs) of 322.59 ± 57.92 IU/Lh, which was similar to the
mean AUCt after a single subcutaneous dose of 225 IU of
urofollitrophin in study 5 (306.82 ± 68.37 IU/Lh).
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Conclusions In our studies, the intramuscular and subcu-
taneous routes of menotrophin were equivalent; both
menotrophin and urofollitrophin were bioequivalent to
their marketed reference; FSH kinetic parameters follow-
ing injection of urofollitrophin were dose proportional and
independent from the administered concentration; and
multiple doses of FSH increased estradiol levels and
enhanced growth of follicles with a good dose–response
correlation. Local tolerability was excellent throughout the
six studies.
Key Points
Two new highly purified human menotrophin and
highly purified urofollitrophin (hp-FSH) preparations
endowed with a higher purification grade
administered as single and multiple doses to healthy
women, pituitary suppressed by oral hormonal
contraceptives, showed excellent local tolerability.
The pharmacokinetics of follicle-stimulating
hormone (FSH) showed bioequivalence of both new
preparations to their marketed references.
The pharmacokinetics of FSH following injection of
hp-FSH was dose proportional and independent from
the administered concentration.
Multiple doses of hp-FSH stimulated estradiol
elevation and enhanced growth of follicles.
1 Background
Gonadotrophic hormones, including follicle-stimulating
hormone (FSH), luteinising hormone (LH) and human
chorionic gonadotrophin (hCG), have been used to promote
fertility for over 30 years. Urofollitrophin is a biologically
pure urinary FSH (uFSH) preparation. Human menotrophin
(hMG) is a naturally occurring combination of gonado-
trophins that contains both FSH and LH activity in equal
amounts. In hMG, the follicle-stimulating activity is of
pituitary origin while the luteinising activity is predomi-
nantly of pituitary origin, but it may also contain luteinis-
ing activity of placental origin. hMG is obtained from the
urine of postmenopausal women but, where necessary,
hCG obtained from the urine of pregnant women may be
added.
The secretion of gonadotrophic hormones in normal
fertile women occurs in a pulsatile manner in response to
hypothalamic pulses. The levels of FSH and LH vary with
the menstrual cycle and show characteristic preovulatory
peaks called surges. Serum FSH levels at which follicle
growth is initiated range individually between 5.7 and 12.0
international units (IU)/L [1–3]. Median serum FSH levels
measured in a sample of 42 healthy volunteers with a
normal menstrual cycle during the follicular phase were 4.0
(range 0.9–9.2) IU/L on cycle day 1, 6.6 (range
4.3–12.5) IU/L at the peak (maximum) concentration
(Cmax) occurring on cycle day 5 (range 1–9) and 3.3 (range
0.8–5.7) IU/L at the minimum occurring on cycle day 13
(range 8–16) [3, 4]. After menopause, the gonadotrophin
secretion is greatly increased in the absence of inhibitory
signals. Therefore, postmenopausal women have high
concentrations of FSH and LH. Median FSH was 51.9
(range 11.3–116) IU/L in a sample of 33 postmenopausal
women [5] and FSH had a geometric mean of 45.7 IU/L in
a sample of 157 postmenopausal women [6].
Urine from postmenopausal women has represented a
source of natural human hMG and FSH for more than
60 years. The first use of gonadotrophins to induce ovu-
lation in hypogonadic women dates back to the work of
Gemzell et al. [7], and the first successful pregnancy
resulting from treatment with urinary gonadotrophins was
reported by Lunenfeld et al. [8, 9]. However, hMG was
purified and isolated from crude extracts of large urine
pools by Breadbury et al. [10]. The first preparation of
urinary hMG was registered for clinical use in Italy in
1950. The older preparations of urinary hMG and FSH
contained small peptidic impurities, which may affect
follicle recruitment and development [11–13]. The urine
contaminants, present in the older preparations of urinary
hMG and FSH, prevented the use of the subcutaneous route
due to potential local reactions [14, 15], though several
clinical studies indicated that the risk of allergic reactions
was minimal [16, 17]. More recently, the new highly
purified FSH (hp-FSH) and highly purified hMG (hp-hMG)
preparations have reached a higher purification grade
equivalent to that of FSH obtained by recombinant DNA
technology (rFSH) [18]. Their purification grade allows a
safe and well-tolerated subcutaneous administration. With
regard to efficacy, recent meta-analyses have confirmed
that hp-FSH, hp-hMG and rFSH are equally effective in
controlled ovarian stimulation within assisted reproductive
technology (ART) programmes [19–23]. Therefore, the
costs of the available formulations have been recently
taken into account as discriminating features [24].
The preparations tested in the studies presented in this
article contain hp-hMG and hp-FSH obtained via a novel
patented purification method. IBSA (Institut Biochimique
S.A., Pambio-Noranco, Switzerland) hp-FSH and hp-hMG
preparations are commercially available worldwide, in 65
and 45 countries, respectively.
Briefly, the purification process starts from urine from
postmenopausal women. After some initial ultrafiltration
and solvent precipitation steps, a highly purified material is
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obtained after a series of chromatography (ion exchange,
affinity and hydrophobic interaction) and filtration steps. A
high level of viral safety of the purified material is also
achieved by the application to the process of several vali-
dated virus clearance procedures. As previously noted,
when necessary, hCG from urine of pregnant women is
added to achieve the 1:1 FSH to LH activity ratio.
Previous literature studies concluded that FSH had a
similar pharmacokinetic profile both after administration of
older urinary preparations or of new highly purified
preparations [25], suggesting that the novel urine purifica-
tion processes to obtain highly purified preparations do not
affect the pharmacokinetic profile of FSH. The main
advantage of the new highly purified preparations is the
almost total absence of contaminants, which allows sub-
cutaneous administration, thus improving the patients’
comfort, ease of use of the product and the batch-to-batch
consistency [26, 27].
Hp-hMG and hp-FSH are indicated for (1) the induction
of ovulation in amenorrhoeic or anovulatory women who
have not responded to treatment with clomiphene citrate;
and (2) controlled ovarian hyperstimulation within an ART
programme—induction of multiple follicular development
in women undergoing assisted reproduction techniques
such as in vitro fertilisation. Both gonadotrophins are also




Hp-hMG and hp-FSH were investigated in six phase I trials
(Table 1). Single-dose studies were all designed as open-
label, randomised, crossover studies with a washout inter-
val of at least 14 days between the two consecutive doses
in studies 1–3 and of at least 28 days in studies 4–5.
The first two trials investigated hMG. In detail, study 1
aimed at comparing the pharmacokinetic profile of FSH
after subcutaneous and intramuscular injection of hp-hMG.
Study 2 compared the pharmacokinetic profile of FSH after
subcutaneous injection of hp-hMG and of a marketed
reference.
Table 1 Summary of the reported phase I studies
Study Preparations Route Dose frequency Dose n Blood sampling
1 hp-hMGa sc Single, 2 periods 300 IU (2 9 150 IU vials) 18 At pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16,
24, 30, 36, 48, 72, 96, 144 and 192 h post-doseim
2 hp-hMGa sc Single, 2 periods 300 IU (4 9 75 IU vials) 18
hp-hMGb
3 hp-FSHc sc Single, 2 periods 300 IU (4 9 75 IU vials) 18
hp-FSHd
4 hp-FSHc sc Single, 2 periods 300 IU (2 9 150 IU vials) 28 At-15,-10 and-0.5 h pre-dose and 1.5, 3, 6, 8, 9, 12,
14, 16, 18, 20, 24, 28, 32, 36, 40, 48, 60, 72, 96, 120,
144 and 192 h post-dose
300 IU (4 9 75 IU vials)
5 hp-FSHc sc Single, 2 periods 225 IU (3 9 75 IU vials) 26 At -15, -10 and -0.05 h pre-dose and 1.5, 3, 6, 9, 12,
14, 16, 18, 20, 24, 28, 32, 36, 40, 48, 60, 72, 96, 120,
144 and 192 h post-dose
445 IU (3 9 150 IU vials)
6 hp-FSHc sc Multiple (5 days) 225 IU (1 9 75 IU vial ?
1 9 150 IU vial)
13 For FSH assay at -1, -0.5 and -0.05 h before the first
dose (i.e. -97, -96.5 and -96.05 h before the fifth
dose), -72, -48 and -24 h before the last (fifth) dose
and 0, 1, 2, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96, 144 and
192 h after the fifth dose
For estradiol assay at -1, -0.5 and -0.05 h before the
first dose of FSH (i.e. -97, -96.5 and -96.05 h
before the fifth dose), -72, -48 and -24 h before the
last (fifth) dose of FSH and 0, 24, 48, 72, 96, 144 and
192 h after the fifth dose of FSH
hp-hMG highly purified human menotrophin, hp-FSH highly purified follicle-stimulating hormone, IBSA Institut Biochimique S.A., im intra-
muscular, IU international units, sc subcutaneous
a Merional, IBSA
b Menopur, Ferring Pharmaceuticals
c Fostimon, IBSA
d BravelleTM, Ferring Pharmaceuticals
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The last four trials investigating hp-FSH were concur-
rent with the formulation development. The study aims
were to compare the pharmacokinetic profile of FSH after
subcutaneous injection of the tested formulation and of a
marketed reference (study 3); to compare the pharma-
cokinetic profile of FSH after subcutaneous injection of the
same dose of the tested formulation administered in two
different concentrations (study 4); to investigate the dose
linearity of FSH after single subcutaneous dose at two
increasing strengths (study 5); and to investigate the
pharmacokinetic profile and the pharmacodynamic effects
of FSH after multiple subcutaneous doses (study 6).
2.1.1 Study Population and Criteria for Inclusion
All six studies were performed at the Phase I Unit of
CROSS Research S.A. (Arzo, Switzerland).
It was planned that 121 healthy fertile women would be
included in the six trials according to the following main
inclusion criteria: (1) age of 18–40 years; (2) body mass
index between 18 and 30 kg/m2; (3) good health based on
medical history, physical examination, a 12-lead electro-
cardiogram (ECG) and routine haematology and blood
chemistry tests; (4) use of a combined oral contraceptive
(estrogen–progestin combined preparation) for at least
3 months prior to the study start; and (5) willingness to
provide written informed consent.
The main exclusion criteria were (1) pregnancy; (2)
intake of any medication; (3) history of drug, alcohol,
caffeine or tobacco abuse; (4) history of an abnormal
menstrual cycle; (5) history of any endocrine, ovarian or
genitourinary abnormality or disease; and (6) a positive
Pap test result.
In order to reduce the variability caused by the
endogenous release of FSH and LH, all women partici-
pating in the studies used their usual oral combined con-
traceptive during the whole study period. After 1 week of
withdrawal, the intake of the contraceptive started from
about 20 days before the first dose of the tested drug until
the end of the study to ensure pituitary suppression.
The sample size for the first three studies (n = 18) was
calculated using the FSH area under the plasma concen-
tration–time curve (AUC) of serum FSH versus time
reported in the literature [28–30]. For the calculation of the
sample size of the first three studies, the Westlake method
for bioequivalence studies was applied [31, 32]. With a
coefficient of variation (CV) of 0.2073, the a-error fixed at
0.05 and a 20 % equivalence limit difference, a crossover
study enrolling 16 volunteers (32 observations) would have
provided a 95 % power. The number of 18 subjects was
considered to have sufficient power to give information on
the actual pharmacokinetic response.
The sample size for study 4, n = 28, was calculated
using the Schuirmann two one-sided t-test [33, 34] and the
same data used for the previous studies [30]. Percentage
CV (CV %) = 22 was set according to the hypothesis that
a higher inter-subject variability was to be expected than
that reported in the literature. With a hypothetical CV
% = 22, a = 0.05 and an 80 % power, n was 24. Taking
into account a rate of four subjects failing to meet the
endogenous FSH suppression criterion, 28 healthy women
were enrolled in order to have 22 subjects to be considered
in the pharmacokinetic analysis.
The sample size of study 5 was calculated using
Schuirmann two one-sided test equivalence analysis of
mean ratios. Results of study 4 were used and the CV was
set to 0.268 and the within-subject correlation to 0.0. The
bioequivalence acceptance range of 80.00–125.00 % was
used. A total of 26 pairs were required to achieve 80 %
power with an a level of 5 %.
The sample size of study 6 was not calculated using any
statistical procedure. A sample of 13 subjects was deemed
sufficient to achieve the main study objective.
2.1.2 Investigational Treatments and Dose Regimens
In the first two studies, single doses of hp-hMG were
administered in two subsequent periods. Single doses of
300 IU were administered using 2 9 150 IU vials and
4 9 75 IU vials in studies 1 and 2, respectively. In study 1,
each subject received one intramuscular and one subcuta-
neous injection of hp-hMG (Merional, IBSA). In study 2,
each subject received two single subcutaneous injections
[Merional, IBSA, test formulation, and Menopur, Fer-
ring Pharmaceuticals (Saint-Prex, Switzerland), reference
formulation].
In studies 3, 4 and 5, two single subcutaneous injections
of hp-FSH were administered in two crossover periods. In
study 3, single doses of 300 IU were administered using
4 9 75 IU vials (Fostimon, IBSA, test formulation, and
BravelleTM, Ferring Pharmaceuticals, reference formula-
tion). In study 4, single doses of 300 IU were administered
using 2 9 150 IU vials (Fostimon, IBSA) in one period
and 4 9 75 IU vials (Fostimon, IBSA) in the other per-
iod. In study 5, single doses of 225 IU (3 9 75 IU vials)
(Fostimon, IBSA) and of 445 IU (3 9 150 IU vials)
(Fostimon, IBSA) were given in the two crossover
periods.
In study 6, each subject received multiple subcutaneous
doses of 225 IU of hp-FSH once a day for 5 days. Each
dose was prepared by combining one 75 IU vial with one
150 IU vial (Fostimon, IBSA). The multiple-dose treat-
ment started on day 21 of intake of an oral combined
contraceptive.
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2.1.3 Ethical Procedures
The documentation of the six studies was reviewed and
approved by the independent ethics committee of Canton
Ticino before each study initiation (from 2000 to 2012).
The Swiss Federal Health Authorities (Swissmedic)
approved and authorised each study. All of the studies were
conducted in compliance with the Swiss ordinance on
clinical trials of therapeutic agents and in accordance with
the Declaration of Helsinki and the general principles of
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) Harmonised Tripartite Guidelines for
Good Clinical Practice (GCP). Subjects of any study did
not undergo any study procedure before signing the written
informed consent form.
2.1.4 Pharmacokinetic and Pharmacodynamic Variables
and Data Analysis
In the calculation of pharmacokinetic parameters, baseline
FSH values were subtracted from each post-dose concen-
tration value. Similarly, estradiol concentrations measured
in study 6 were baseline subtracted.
In the first four studies, the parameters were also cor-
rected for the actual administered dose, taking into account
both the actual strength of the used finished products and
the residual product measured in the used vials after
injections. In study 5, the AUC from administration to the
last observed concentration time t (AUCt) and Cmax were
compared between treatments, after normalisation for the
dose.
The following pharmacokinetic parameters were mea-
sured and/or calculated for FSH, when feasible, using
Kinetica version 4.0 or higher (Thermo Scientific,
Philadelphia, PA, USA) or WinNonLin 6.3 (Pharsight,
Cary, NC, USA): Cmax, tmax (time to achieve Cmax), t
(elimination half-life, calculated, as ln2/kz, where kz is the
terminal elimination rate constant, calculated by log-linear
regression using at least 3 points), AUCt calculated with
the linear trapezoidal method, AUC? (AUC from time
zero to infinity, calculated, if feasible, as AUCt ? Ct/kz,
where Ct is the last measurable drug concentration) and
AUCs (AUC during the time interval s between two con-
secutive doses at steady state).
In studies 1–5, the Cmax and AUC values of FSH were
compared using analysis of variance (ANOVA) for a
crossover design on log-transformed data. In study 5, the
analysis was performed after dose normalisation. Schuir-
mann two one-sided t-tests at the level of significance of
5 % were also performed. The acceptance criterion for
bioequivalence, and for linearity in study 5, was that the
90 % confidence intervals (CIs) of the ratios of the
parameter geometric means were within the 80–125 %
range.
The follicular growth stimulation was evaluated in
study 6 as the pharmacodynamic effect of FSH. The
number and the size of follicles were determined by
ultrasonography. The development of follicles in both
ovaries was evaluated at screening and on days 26 and
35–37, i.e. on the fifth treatment day and 10–12 days after
the end of the treatment.
2.1.5 Sample Collection, Handling and Analytics
Venous blood samples were collected for the determination
of FSH in serum (studies 1, 3, 4, 5 and 6) or plasma
(study 2) and of estradiol in serum (study 6) at the sam-
pling timepoints reported in Table 1. The suppression of
endogenous FSH was verified measuring the endogenous
FSH from 3 days to 1 day before the first dose in the first
three studies, at the screening and then on the day before
the first dose in studies 4 and 5, and on day 20 (i.e. 2 days
before the start of treatment) in study 6.
In the first three studies, one pre-dose sample was col-
lected in each study period, while three pre-dose samples
were collected in the last three studies. In the last three
studies, baseline FSH was calculated as arithmetic mean of
the three pre-dose values. In all six studies, blood samples
were collected up to 192 h post-dose after each single dose
and after the last dose in study 6. Serum and plasma
samples were stored frozen at or below -20 C until
analysed.
FSH was determined at the following qualified bioana-
lytical laboratories:
• Studies 1 and 2: Institut Dr Viollier, Basel, Switzerland,
and Bio-Inova, Plaisir, France, respectively, both using
a chemiluminometric sandwich immunoassay, Advia
Centaur, Bayer, with a lower quantification limit
(LQL) of 0.3 IU/L and a precision CV ranging from 2.2
to 3.9 %.
• Study 3: CentraLabS Clinical Research Ltd., Alcon-
bury, UK using a validated modified radioimmunoassay
(Coat-a-Count IRMA, Euro DPC Ltd, UK) with a
LQL of 0.4 IU/L. The calibration range covered
0.19–15 IU/L. Accuracy: bias ranged from -4.3 to
20.8 % for the quality control (QC) samples. Precision:
CV ranged from 1.9 to 40.0 % for the QC samples.
• Study 4: Nuvisan GmbH, Neu-Ulm, Germany using a
validated two-site immunoradiometric assay with a
LQL of 0.300 IU/L. The calibration range covered
0.000–28.0 IU/L. Accuracy: bias ranged from -3.92 to
3.57 %. Precision: CV ranged from 2.23 to 8.06 % for
the QC samples.
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• Study 5: Analytical Biochemical Laboratory B.V., Assen,
Netherlands. The applied validated method was a solid-
phase two-site fluoroimmunometric assay in which two
monoclonal antibodies were directed against two separate
antigenicdeterminants on theFSHmolecule.TheLQLwas
0.250 IU/L. The calibration range covered 0.250–500 IU/
L. Accuracy: bias ranged from-4.4 to-2.4 % for the QC
samples. The inter-day CV and mean bias values for the
calibration standards ranged from 0.5 to 1.6 % and-1.0 to
1.1 %, respectively.
• Study 6: Analytical Biochemical Laboratory B.V. The
LQL and calibration range were as for study 5. Accuracy:
bias ranged from-9.6 to-5.4 % for theQC samples. The
inter-run CV and mean bias values for the calibration
standards ranged from 0.4 to 1.9 % and -1.2 to 0.5 %,
respectively. Estradiol was measured by the validated
methodWallac AutoDelfia Fluoroimmunoassay at Ana-
lytical Biochemical Laboratory B.V. with an LQL of
13.6 pg/mL. The calibration range covered
13.6–4059 pg/mL. Accuracy: bias ranged from -7.4 to
-5.6 % for the QC samples. The inter-run CV values for
the calibration standards was 0.0 % and mean bias ranged
from-0.3 to 0.0 %.
2.1.6 Safety Variables
Safety measures included the recording of adverse events,
the measurement of vital signs, ECG recording, full
physical examinations and routine haematology, blood
chemistry and urinalysis laboratory tests. In all studies,
local reactions and pain at the injection site were evaluated
by the volunteers. Adverse events were defined as any
untoward medical occurrences in study subjects receiving
the study treatment and which did not necessarily have to
have a causal relationship with the study treatment. For
each reported adverse event, the relationship with study
treatment, when assessable, was classified as certain,
probable, possible or unlikely/none and intensity was
classified as mild, moderate or severe.
3 Results
3.1 Disposition of Subjects
Altogether, 121 healthy fertile women were enrolled and
received at least one dose of the studied formulations. In
study 1, one of 18 subjects withdrew prematurely from the
study due to personal reasons. In study 5, one of 26 sub-
jects prematurely withdrew consent to take part in the study
for personal reasons. In study 6, one of 13 subjects wished
to leave the study prematurely for personal reasons after
receiving two doses of the investigational treatment. All
other enrolled and randomised subjects completed as per
protocol each study they were taking part in. No discon-
tinued subject was included in any pharmacokinetic anal-
ysis. All completers were considered in the
pharmacokinetic analysis of each study with the exception
of study 4, in which 28 subjects were enrolled. Twenty-two
of the subjects were included in the pharmacokinetic
analysis, while the remaining six subjects were excluded
from the pharmacokinetic analysis due to baseline FSH
values C2 IU/L and were considered in the safety analysis
only.
3.2 Follicle-Stimulating Hormone (FSH)
Pharmacokinetic Profile After a Single Dose
of Highly Purified Human Menotrophin
FSH mean serum levels after single subcutaneous and
intramuscular injection of hp-hMG (study 1) and after single
subcutaneous injection of the hp-hMG test formulation
(study 2) are reported in Fig. 1. Systemic FSH concentra-
tions, measured in study 1, are very similar after single
intramuscular and subcutaneous injection and the pharma-
cokinetic analysis suggested the equivalence of the two
Fig. 1 Mean serum follicle-stimulating hormone concentration–time
curves after single subcutaneous and intramuscular injections of
highly purified human menotrophin (top study 1, n = 17; bottom
study 2, n = 18). Error bars indicate ?standard deviation. FSH
follicle-stimulating hormone, hp-hMG highly purified human meno-
trophin, i.m. intramuscular, IU international units, s.c. subcutaneous
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administration routes for the tested formulation (90 % CI
105–122 for AUCt and 90 % CI 103–127 for Cmax).
Study 2 demonstrated the bioequivalence of the hp-
hMG formulation versus the marketed reference (90 %
CI 80.24–100.2 for AUCt and 90 % CI 81.5–99.01 for
Cmax). Table 2 summarises the FSH pharmacokinetic
parameters measured and calculated after baseline sub-
traction and correction for the actually administered dose
after a single dose of hp-hMG in studies 1 and 2.
3.3 FSH Pharmacokinetic Profile After a Single
Dose of Highly Purified FSH (hp-FSH)
Study 3 demonstrated the bioequivalence of the hp-FSH
formulation versus the marketed reference (90 % CI
91.4–107.8 for AUCt and 90 % CI 92.6–111.9 for Cmax;
see Table 3 for pharmacokinetic parameters and Fig. 2 for
FSH mean serum levels after a single subcutaneous injec-
tion of the test formulation).
Study 4 proved the equivalence of the tested hp-FSH
formulation manufactured at two different strengths (150
vs. 75 IU vials) administered at the same dose (300 IU)
(90 % CI 82–94 for AUCt and 90 % CI 83–93 for Cmax;
Table 3; Fig. 2).
Study 5 showed the pharmacokinetic linearity of FSH
administered as one single dose of 225 IU (3 9 75 IU vials)
and of 445 IU (3 9 150 IU vials) (see Fig. 2; Table 3).
3.4 FSH Pharmacokinetic Profile After Multiple
Doses of hp-FSH
The mean serum levels of FSH and estradiol during treat-
ment and after the fifth dose of hp-FSH are reported in Fig. 3.
Pharmacokinetic parameters of baseline-corrected
serum FSH after the fifth (last) injection of hp-FSH are
presented in Table 4. The mean AUCs was similar to the
mean AUC? of serum FSH after a single dose of 225 IU of
hp-FSH measured in study 5 (compare data in Table 4 with
that in Table 3), thus denoting the linearity and time
independence of FSH clearance.
The number of follicles is depicted by size and by
timepoint in Fig. 4.
Table 2 Main pharmacokinetic parameters of baseline-corrected serum follicle-stimulating hormone; data are reported as mean ± standard
deviation
Study n Route Arm Cmax (IU/L) tmax (h) AUCt (IU/Lh) AUC? (IU/Lh) t (h)
1 17 im 6.5 ± 2.1 19.4 ± 7.4 438.0 ± 124.0 486.6 ± 131.3 45.2 ± 12.1
sc 7.5 ± 2.8 21.8 ± 9.3 485.0 ± 93.5 525.8 ± 95.8 41.1 ± 8.6
2 18 sc A 5.80 ± 1.55 19.89 ± 6.12 431.04 ± 135.06 470.45 ± 190.78 45.28 ± 18.73
B 6.36 ± 1.48 27.33 ± 10.54 474.26 ± 120.06 499.3 ± 129.29 39.02 ± 11.51
AUC? area under the plasma concentration–time curve from time zero to infinity, AUCt area under the plasma concentration–time curve from
administration to the last observed concentration time t, Cmax peak (maximum) concentration, FSH follicle-stimulating hormone, hp-hMG highly
purified human menotrophin, im intramuscular, IU international units, t elimination half-life, tmax time to achieve Cmax, sc subcutaneous
Study 1: single sc and im dose of the tested hp-hMG
Study 2: single sc dose of the tested hp-hMG (A) and of the reference hp-hMG (B)
Table 3 Main pharmacokinetic parameters of baseline-corrected serum FSH; data are reported as mean ± standard deviation
Study n Arm Cmax (IU/L) tmax (h) AUCt (IU/Lh) AUC? (IU/Lh) t (h)
3 18 A 5.74 ± 0.95 21.33 ± 9.18 486.16 ± 91.13 541.22 ± 113.83 48.96 ± 12.27
B 5.79 ± 1.09 25.67 ± 5.99 476.90 ± 85.40 529.34 ± 90.88 45.23 ± 9.31
4 22 C 4.98 ± 1.16 21.36 ± 8.43 409.71 ± 109.61 441.35 ± 108.85 48.28 ± 12.68
D 5.75 ± 1.71 22.0 ± 7.09 473.62 ± 139.61 515.27 ± 155.89 53.63 ± 16.15
5 25 E 4.05 ± 0.78 22.60 ± 7.44 306.82 ± 68.37 330.72 ± 78.56 41.41 ± 14.26
F 10.02 ± 1.58 22.24 ± 5.64 716.68 ± 124.03 765.84 ± 141.96 41.97 ± 12.48
AUC? area under the plasma concentration–time curve from time zero to infinity, AUCt area under the plasma concentration–time curve from
administration to the last observed concentration time t, Cmax peak (maximum) concentration, FSH follicle-stimulating hormone, hp-FSH highly
purified follicle-stimulating hormone, IU international units, t elimination half-life, tmax time to achieve Cmax, sc subcutaneous
Study 3: single sc doses of 300 IU of tested hp-FSH 4 9 75 IU vials (A) and of reference hp-FSH 4 9 75 IU vials (B)
Study 4: single sc doses of 300 IU of tested hp-FSH 4 9 75 IU vials (C) and 2 9 150 IU vials (D)
Study 5: single sc doses of 225 (E) and 450 IU (F) of tested hp-FSH
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3.5 Safety
The frequency of adverse events reported during the six
studies of FSH is summarised in Table 5. Local reactions
to the injection of hp-hMG and hp-FSH are summarised in
Table 6.
4 Discussion
FSH pharmacokinetics and pharmacodynamics have been
investigated in six clinical studies over a timeframe of
14 years while the two tested hp-hMG and hp-FSH
formulations were being developed. The first five open-la-
belled, randomised, crossover single-dose studies differed
slightly in their designs mainly due to regulatory require-
ments being updated over the years. In particular, a cor-
rection for the actually administered dose and for the
residual product content in the used vials was applied to the
calculation of FSH pharmacokinetic parameters in the first
four studies. Later, this kind of correction was no longer
required by the regulator and was not applied to studies 5
and 6. The sample size calculation for the first three studies
was performed using literature data, whereas the data col-
lected in first three studies advantaged the sample size
calculation for studies 4 and 5. The sample size of study 6
was estimated without any statistical calculation. Healthy
fertile women with a normal menstrual cycle were the
population selected consistently in all six studies. All
enrolled women were pituitary suppressed. The suppression
of endogenous gonadotrophins aimed to reduce the bias in
the pharmacokinetic analysis of FSH. Oral hormonal con-
traceptives were chosen for reasons of safety and compli-
ance, whilst gonadotrophin-releasing hormone agonists
were excluded due to their higher invasiveness towards
healthy subjects. Moreover, the oral contraceptives inhibit
endogenous FSH and LH to at least the same low concen-
trations observed in subjects with hypogonadotrophic
hypogonadism [28–30, 35]. Although complete pituitary
inhibition is not ensured with oral contraceptives [36],
adequate suppression of the hypothalamic–pituitary–ovarian
axis has been demonstrated in the literature [37–40].
Women with endogenous FSH\4 IU/L can be considered
to be under appropriate gonadotrophin suppression [41].
Nevertheless, FSH\2 IU/L, reached by prolonged use of
combined contraceptives, was considered to be an adequate
degree of inhibition [37–40] in the first four studies.
Afterwards, the acceptance level was increased to FSH
\4 IU/L [41, 42]. Baseline values of endogenous FSH
measured pre-dose were subtracted from each post-dose
concentration value. In the last three studies, baseline FSH
and estradiol values were calculated as arithmetic means of
three pre-dose values. This approach was deemed appro-
priate on the basis of analogous literature studies such as
those by le Cotonnec et al. [25, 42, 43] and considering that
the risk of overcorrection of data is mitigated by the
crossover design applied to studies 1–5 [41]. In studies 4–6,
the evaluation of pre-dose levels of endogenous FSH and
estradiol extended to three timepoints, which was also in
compliance with the guidelines on bioequivalence and
bioavailability updated at that time. A 24-h baseline serum
FSH or estradiol profile was deemed unnecessary since
relevant diurnal fluctuations can be excluded for both hor-
mones on the basis of previous literature pharmacokinetic
studies [42, 43]. In fact, FSH and LH are normally secreted
in a pulsatile fashion that does not correlate with day or
Fig. 2 Mean follicle-stimulating hormone serum concentration–time
profiles after single subcutaneous doses of highly purified follicle-
stimulating hormone (top study 3, n = 18; centre study 4, n = 22;
bottom study 5, n = 25). Error bars indicate ?standard deviation.
FSH follicle-stimulating hormone, hp-FSH highly purified follicle-
stimulating hormone, IU international units, s.c. subcutaneous
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night, estrogen or progesterone levels, or waking or sleeping
[44, 45]. More recent research has confirmed the absence of
circadian rhythms of gonadotrophin secretion through con-
stant routine protocols of sleep/wake, light, temperature,
position and nutritional cues across a 24-h period in fertile
and postmenopausal women [46, 47]. In the same study,
estradiol also did not show any significant change in
concentration between evening, night and morning [46].
The washout period was 14 days between two consecutive
injections in studies 1–3, whilst it was prolonged to 28 days
between administrations in studies 4–5. This change
ensured that FSH concentrations returned below the quan-
tification level in all subjects before administration of the
second period, thus avoiding any carry-over effect.
Table 4 Pharmacokinetic parameters of baseline-corrected serum follicle-stimulating hormone after five daily 225 IU doses of highly purified
follicle-stimulating hormone (study 6, n = 12)
Cmax (IU/L) tmax (h) AUCs (IU/Lh) kz (1/h) t (h)
Mean ± SD 14.93 ± 2.92 11.58 ± 5.47 322.59 ± 57.92 0.03 ± 0.01 28.66 ± 9.58
Median (range) 15.08 (10.52–21.17) 12.0 (4–24) 327.37 (232.93–452.42) 0.03 (0.01–0.04) 26.41 (15.74–50.42)
s: 0–24
kz terminal elimination rate constant,, AUCs area under the plasma concentration–time curve during the time interval s between two consecutive
doses at steady state, Cmax peak (maximum) concentration, FSH follicle-stimulating hormone, hp-FSH highly purified follicle-stimulating

































13-15 mm 10-12 mm
7-9 mm 4-6 mm
1-3 mm
Fig. 4 Mean number of
follicles by size category at
baseline and after treatment
with highly purified follicle-
stimulating hormone (study 6,
n = 12), counted at the
screening visit on the fifth day
of treatment and 10–12 days
after the end of the treatment
Fig. 3 Mean serum follicle-
stimulating hormone (IU/L) and
estradiol (pg/mL) original
concentration–time profiles
(study 6, n = 12). Error bars
indicate ?standard deviation.
E2 estradiol, FSH follicle-
stimulating hormone, IU
international units
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After a single dose of 300 IU of hp-hMG and of hp-
FSH, the FSH concentration versus time curves and
pharmacokinetic parameters were substantially similar.
Both the hp-hMG and the hp-FSH formulations were
bioequivalent to their respective marketed references in
terms of the Cmax and AUC of systemic FSH after a single
subcutaneous injection. The equivalence between the
subcutaneous and intramuscular routes of administration
of hp-hMG was proven for FSH AUCt, the 90 % CIs of
which met the usually applied acceptance range of
80.00–125.00 %. On the other hand, Cmax had a larger
inter- and intra-individual variability and 90 % CI
accounting for 103–127 %.This result proved the equiv-
alence of the two administration routes in terms of the
extent of absorption and is consistent with literature data
for similar studies [30]. Furthermore, two different
strength formulations (150 vs. 75 IU vials) also proved to
be bioequivalent.
In the five single-dose studies after subcutaneous or
intramuscular administration of hp-hMG and hp-FSH, the
FSH pharmacokinetic profile in the dose range 225–445 IU
showed (1) a slow absorption from the injection site (tmax
C20 h); (2) a sustained elimination from the central com-
partment (t[40 h); (3) linear pharmacokinetics; and (4)
bioavailability independent from the route and the mode of
administration (subcutaneous vs. intramuscular route or use
of different strength formulations). The pharmacokinetic
results of FSH obtained in the studies reported here are
consistent with those of the literature [48, 49]. In particular,
FSH was dose proportional after single subcutaneous
injections of hp-FSH in the dose range 225–445 IU
according to the results of study 5, similar to results pre-
viously published in the literature [48, 49]. In detail,
Mannaerts et al. [48] investigated the pharmacokinetics of
FSH after multiple intramuscular doses of 75, 150 and
225 IU/day of rFSH for 7 days in gonadotrophin-deficient
subjects and after multiple intramuscular doses of 75, 150
and 225 IU/day of rFSH and 150 IU/day of uFSH in
pituitary-suppressed subjects. In the multiple rising dose
study of rFSH in gonadotrophin-deficient subjects, serum
FSH concentrations increased in a dose-dependent manner
consistent with the results of study 5. Mannaerts et al.
[50, 51] observed that FSH was at steady state within
5 days of treatment, which was consistent with the data in
Table 5 Frequency of adverse events [n (%)]
Adverse events hp-hMG hp-FSH





























Headache 0 (0) 5 (13.89) 0 (0) 10 (21.74) 4 (15.4) 6 (24) 2 (15.4)
Nausea 0 (0) 1 (2.78) 0 (0) 2 (4.35) 0 (0) 2 (8) 0 (0)
Vomiting 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (8) 0 (0)
Eosinophilia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.7)
Hyperprolactinaemia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.7)
Metrorrhagia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.7)
Vaginal haemorrhage 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.7)
Skin reaction 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.7)
Abdominal discomfort 0 (0) 0 (0) 0 (0) 2 (4.35) 0 (0) 1 (4) 0 (0)
Breast tension 0 (0) 0 (0) 0 (0) 2 (4.35) 0 (0) 0 (0) 0 (0)
Erythema at the injection
site
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4) 0 (0)
Abdominal pain 0 (0) 0 (0) 0 (0) 0 (0) 1 (3.8) 0 (0) 0 (0)
Haematoma at the
injection site
0 (0) 1 (2.78) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Candidiasis 0 (0) 0 (0) 0 (0) 1 (2.17) 0 (0) 0 (0) 0 (0)
Upper respiratory tract
infection
0 (0) 0 (0) 0 (0) 1 (2.17) 0 (0) 0 (0) 0 (0)
Cervicalgia 0 (0) 0 (0) 0 (0) 1 (2.17) 0 (0) 0 (0) 0 (0)
Catheter-site phlebitis 0 (0) 0 (0) 0 (0) 1 (2.17) 0 (0) 0 (0) 0 (0)
hp-FSH highly purified follicular stimulating hormone, hp-hMG highly purified human menotrophin, IU international units
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the literature. In the gonadotrophin-deficient subjects,
steady state was achieved after 3–5 days [48]. In the
multiple subcutaneous dose study (study 6), serum FSH
increased over the physiological baseline concentration
and, on average, attained a peak at 12 h after the last
injection. On the fifth treatment day, systemic FSH attained
96.87 % of steady state and AUCs was consistent with the
data in the literature. Afterwards, the FSH concentration
declined and, on average, returned to the baseline levels at
192 h after the last injection.
The FSH pharmacokinetic parameters obtained after
multiple subcutaneous doses of hp-FSH (study 6) are
consistent with those of the literature [42, 48, 49] for rFSH.
In particular, Cmax is consistent with the data in the liter-
ature, though the treatment duration was 7 days in the lit-
erature studies of uFSH (150 IU intramuscular) [48] and of
subcutaneous rFSH (225 IU) [49] and (150 IU) [42]. AUCs
is also consistent with the same literature data [42, 48, 49].
Results from study 6 are compared with those of the lit-
erature in Table 7.
As expected [49], multiple subcutaneous injections of hp-
FSH administered to pituitary-suppressed subjects were able
to stimulate the increase in endogenous estradiol levels.
According to the observations of study 6, the baseline-cor-
rected estradiol concentration attained a peak at 48 h after
the fifth injection of hp-FSH. Seven days after the end of the
treatment (192 h after the last injection), serum estradiol fell
to levels very close to the baseline. Generally, follicular
growth and development can also take place with extremely
low levels of estrogens in women treated with hp-FSH
[27, 52]. Notably, the effect on follicular estrogen production
depends on the presence and the amount of endogenous LH
when pure exogenous FSH is administered [27]. Previous
literature studies demonstrated that minimal LH levels are
sufficient to sustain the secretion of estradiol in response to
the treatment with hp-FSH evenwhen the pituitary activity is
suppressed [48, 53]. In other words, according to the spec-
ulations by Mannaerts et al. [48] and Devroey et al. [53], a
persisting minimal production of endogenous LH is suffi-
cient to concurwith the exogenous FSH to stimulate estrogen
biosynthesis and secretion in women with a normal men-
strual cycle, even if under pituitary suppression. In conclu-
sion, the results of study 6 show consistency with the data in
the literature.
After multiple subcutaneous doses of hp-FSH, the
observed increase in the mean follicular size showed a
qualitative correlation with the increase in estradiol levels
and both correlated with the pharmacokinetics of FSH. The
pharmacodynamic effect of FSH was appreciable on the
fifth treatment day when the majority of the follicles, which
had a size of 1–3 mm at baseline, attained a size of
7–9 mm after five doses. The follicular growth showed a
good correlation with the increase in estradiol concentra-
tion. In fact, the women who showed the highest estradiol
Table 6 Local tolerability at the site of injection [n (%)]
Local reaction hp-hMG hp-FSH

































Erythema 0 (0) 1 (5.56) 0 (0) 1 (2.17) 0 (0) 1 (4) 0 (0)
Swelling 0 (0) 2 (11.11) 1 (5.56) 6 (13.04) 0 (0) 0 (0) 0 (0)
Itching 0 (0) 0 (0) 0 (0) 1 (2.17) 2 (7.7) 1 (4) 1 (7.7)
Mild pain at the site of injection limited to
the time of injection
16 (44.44) 7 (38.89) 12 (66.67) 27 (58.70) 5 (19.2) 5 (20) 3 (23)
Moderately severe pain at the site of
injection limited to the time of injection
4 (11.11) 2 (11.11) 2 (11.11) 0 (0) 0 (0) 0 (0) 0 (0)
Mild pain at the site of injection lasting up to
1 h
0 (0) 0 (0) 1 (5.56) 0 (0) 0 (0) 0 (0) 0 (0)
Moderately severe pain at the site of
injection lasting up to 1 h
1 (2.78) 1 (5.56) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mild pain at the site of injection lasting
longer than 4 h
1 (2.78) 2 (11.11) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Moderately severe pain at the site of
injection lasting longer than 4 h
0 (0) 1 (5.56) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
hp-FSH highly purified follicular stimulating hormone, hp-hMG highly purified human menotrophin, IU international units
Follicle-Stimulating Hormone Pharmacokinetics 1041
levels at the end of the treatment (206.07 and 614.93 pg/
mL) also had the highest number of follicles C7 mm. Up to
12 days later, the effect of FSH on the follicles had
diminished inasmuch as the majority of the follicles had a
size of 4–6 mm. The present results in terms of number and
size of follicles are consistent with data published by
Voortman et al. [49]. In particular, the number of follicles
in the size categories of 7–9 and 10–12 mm observed on
the fifth day of treatment with subcutaneous injections of
225 IU of hp-FSH are in agreement with the number of
follicles in the size categories 8–9.9 and 10–11.9 mm
observed by Voortman et al. [49] on the fifth day of
treatment with 225 IU of rFSH.
Meanwhile, the clinical efficacy of both hp-hMG and
hp-FSH as tested in the studies reported here has been
demonstrated in phase III studies [54, 55].
With respect to the safety of both hp-hMG and hp-FSH,
the only untoward effect with a frequency [10 % was
headache, the frequency of which showed a correlation
with the dose. Indeed, the highest frequency of headache
observed across the six studies (24 %) was reported for the
hp-FSH dose of 445 IU. Notably, headache had a fre-
quency of 15.4 % in study 6 during the multiple-dose
treatment. All other reported untoward effects had a fre-
quency B8 %. Nausea and vomiting were reported at a
frequency of 8 % with 445 IU of hp-FSH. No adverse
events were reported after a single dose of the marketed
references in studies 2 and 3.
With respect to local tolerability, the injections of hp-
hMG and hp-FSH were mildly painful for about 20–60 %
of the subjects. Painful injections of moderate severity
occurred at a lower frequency than did mildly painful
injections. Painful injections of moderate severity also had
a lower frequency with the test treatments than with the
reference treatments (studies 2–3). Generally, the pain was
limited to the time of injection and did not last longer than
4 h. Other local reactions had a frequency not higher than
15 %, similar to the reference treatments.
5 Conclusions
On the basis of the results of the six clinical trials in
healthy fertile women pituitary suppressed by oral hor-
monal contraceptives, the following conclusions can be
drawn: hp-hMG proved to be equivalent when adminis-
tered by the intramuscular and the subcutaneous routes
in terms of extent of absorption; both hp-hMG and hp-
FSH were bioequivalent to their respective marketed
reference; FSH pharmacokinetic parameters following
injection of hp-FSH were dose proportional and inde-
pendent from the administered concentration; multiple
doses of hp-FSH increased estradiol levels and enhanced
growth of follicles with a good dose-response correla-
tion; and local tolerability was excellent throughout the
six studies.
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